Home > Neurology > EAN 2020 > Headache and Pain > Real-world data for erenumab in Germany

Real-world data for erenumab in Germany

Presented By
Prof. Andreas Straube, Ludwig-Maximilians-University Munich, Germany
Conference
EAN 2020
Trial
TELESCOPE
Based on the assessment of treating physicians, erenumab reduced the burden of migraine and increased the quality of life (QoL) in over 75% of their migraine patients. These were the main results of the TELESCOPE study, providing real-world data for erenumab in Germany [1]. By means of an online survey from July-December 2019, data from 45 headache centres across Germany were collected. The interim analysis included 542 patients. Half of these had episodic migraine, half had chronic migraine. A total of 45 physicians reported that 19% of their patients were currently using monoclonal antibodies. For almost all patients, restricted QoL (100%) and number of mean monthly migraine days (MMD) (98.8%) were the main reasons to start treatment with a monoclonal antibody. Physicians reported that 82.7% of their patients responded to erenumab and that 79.5% were satisfied with it. Erenumab reduced headache intensity in 77.4% of patients, improved QoL in 75.5%, and r...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on